Global drug maker Dr Reddy's Laboratories has announced the launch of Tablet Bispec (solifenacin succinate) in domestic market.

The company claims that Bispec is the best-in-class drug in its segment and has lesser incidence of dry mouth and constipation.

The drug is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

The newly launched drug will be available in tablet form, and in dosages of 5 mg and 10 mg.

Recently, Dr Reddy's has revealed its plan to employ 1,300 people this year, including about 350 through campus recruitment. The company has informed that new recruits would go through the mandatory reorientation program before being put to regular work at the leadership academy at its Bachupally premises.

Leading market experts believe that investors with a long-term horizon can consider buying the stock of Dr Reddy's Laboratories (DRL) due to its strong product pipeline.

Shares of the company closed up Rs 7, or 1%, at Rs 744. The total volume of shares traded at the BSE was 19138 (Tuesday).